CASI Pharmaceuticals Net Income
| CASI Stock | USD 0.94 0.05 5.05% |
As of the 5th of February, CASI Pharmaceuticals shows the Variance of 27.99, market risk adjusted performance of (0.31), and Mean Deviation of 3.72. CASI Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.
CASI Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.2856 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -35.3 M | -37.1 M | |
| Net Loss | -35.3 M | -37.1 M | |
| Net Loss | -33 M | -34.6 M | |
| Net Loss | (2.30) | (2.42) | |
| Net Income Per E B T | 0.93 | 0.61 |
CASI | Net Income | Build AI portfolio with CASI Stock |
The Net Income trend for CASI Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether CASI Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest CASI Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of CASI Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CASI Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of CASI Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CASI Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CASI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (39.26 M) | 10 Years Trend |
|
Net Income |
| Timeline |
CASI Net Income Regression Statistics
| Arithmetic Mean | (24,257,462) | |
| Coefficient Of Variation | (65.32) | |
| Mean Deviation | 13,824,711 | |
| Median | (26,938,000) | |
| Standard Deviation | 15,845,882 | |
| Sample Variance | 251.1T | |
| Range | 48.3M | |
| R-Value | (0.78) | |
| Mean Square Error | 105.1T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | (2,445,843) | |
| Total Sum of Squares | 4017.5T |
CASI Net Income History
Other Fundumenentals of CASI Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CASI Pharmaceuticals Net Income component correlations
CASI Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CASI Pharmaceuticals is extremely important. It helps to project a fair market value of CASI Stock properly, considering its historical fundamentals such as Net Income. Since CASI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CASI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CASI Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
CASI Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CASI Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CASI Pharmaceuticals.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in CASI Pharmaceuticals on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding CASI Pharmaceuticals or generate 0.0% return on investment in CASI Pharmaceuticals over 90 days. CASI Pharmaceuticals is related to or competes with Cingulate, Entero Therapeutics, Curis, Pelthos Therapeutics, NuCana PLC, Palisade Bio, and Allarity Therapeutics. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical pro... More
CASI Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CASI Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CASI Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 32.11 | |||
| Value At Risk | (7.59) | |||
| Potential Upside | 5.88 |
CASI Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CASI Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CASI Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use CASI Pharmaceuticals historical prices to predict the future CASI Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.32) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CASI Pharmaceuticals February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 3.72 | |||
| Coefficient Of Variation | (1,240) | |||
| Standard Deviation | 5.29 | |||
| Variance | 27.99 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 32.11 | |||
| Value At Risk | (7.59) | |||
| Potential Upside | 5.88 | |||
| Skewness | 1.74 | |||
| Kurtosis | 6.8 |
CASI Pharmaceuticals Backtested Returns
CASI Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0923, which signifies that the company had a -0.0923 % return per unit of volatility over the last 3 months. CASI Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CASI Pharmaceuticals' Market Risk Adjusted Performance of (0.31), variance of 27.99, and Mean Deviation of 3.72 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CASI Pharmaceuticals will likely underperform. At this point, CASI Pharmaceuticals has a negative expected return of -0.5%. Please make sure to confirm CASI Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.
Auto-correlation | -0.75 |
Almost perfect reverse predictability
CASI Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between CASI Pharmaceuticals time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CASI Pharmaceuticals price movement. The serial correlation of -0.75 indicates that around 75.0% of current CASI Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.75 | |
| Spearman Rank Test | -0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CASI Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CASI Pharmaceuticals reported net income of (39.26 Million). This is 111.5% lower than that of the Biotechnology sector and 156.05% lower than that of the Health Care industry. The net income for all United States stocks is 106.88% higher than that of the company.
CASI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.CASI Pharmaceuticals is currently under evaluation in net income category among its peers.
CASI Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in CASI Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of CASI Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CASI Pharmaceuticals' value.| Shares | Susquehanna International Group, Llp | 2025-06-30 | 10.2 K | Royal Bank Of Canada | 2025-06-30 | 9.9 K | Ubs Group Ag | 2025-06-30 | 954 | Wells Fargo & Co | 2025-06-30 | 505 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 365 | Blackrock Inc | 2025-06-30 | 296 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 134 | Simplex Trading, Llc | 2025-06-30 | 26.0 | Jpmorgan Chase & Co | 2025-06-30 | 25.0 | Vr Adviser, Llc | 2025-06-30 | 987.3 K | Foresite Capital Management Vi Llc | 2025-06-30 | 787.1 K |
CASI Fundamentals
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (1.84) % | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 34.44 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Shares Owned By Insiders | 62.93 % | ||||
| Shares Owned By Institutions | 39.19 % | ||||
| Number Of Shares Shorted | 60.76 K | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 0.57 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 9.61 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (1.39) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (3.02) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 233 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 15.34 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
| Net Asset | 53.67 M |
About CASI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.